The first child-specific body scan charts could enable physicians to assess obesity risk

A Concordia-led research team has created one of the first reference charts showing how children's adipose (fat) and muscle ...
Hospital for Special Surgery

The Link Between Growth Hormone Therapy and Fracture Risk in Children

For parents whose children are undergoing growth hormone therapy, the focus might be on height and physical development, but ...
Healio

FDA approves Elevidys for pediatric Duchenne muscular dystrophy

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Elevidys, a recombinant gene therapy for pediatric patients with Duchenne muscular ...
Business Wire

Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the ...
University of Delaware

Understanding muscle development

University of Delaware’s Mona Batish is a molecular biologist. She studies circular RNAs formed as a result of so-called molecular mistakes that occur when a strand of RNA — the ribonucleic acid that ...
MedPage Today

Screening for Sleep Disordered Breathing in Children With Spinal Muscular Atrophy

Researchers evaluated oxygen saturation and arterial CO2 variables to screen for sleep disordered breathing in children with SMA type 1-3. Of the measures evaluated, only an oxygen desaturation index ...
Tennessean

Breakthrough gene therapy offers new hope to child with muscular dystrophy

Six-year-old José Capablanca was excited to see his visitors. “I think you guys want to know how fast I can run!” he shouted, racing around his family’s home in Gallatin, Tennessee. José has Duchenne ...
Nasdaq

Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA

BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has ...